TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Closure of Umbilical Hernias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1-5 years~* Umbilical hernia\>1cm. diameter.~* Undergoing either a general surgical or urologic procedure under general anesthesia other than umbilical hernia repair.~* No previous umbilical hernia repair.~Exclusion Criteria:~* Over 5 years~* No umbilical hernia~* No other surgery required~* Previous umbilical hernia repair

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Deflux (Type: EXPERIMENTAL): Treatment with Deflux.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Syph-Check Syphilis Antibody Point of Care (POC) Test

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and Women will be eligible who:~  1. are 18 years of age or older;~ 2. Routine presumed uninfected for screening visit, or show symptomatic signs of infection or are asymptomatic but are suspected of infection, and either/or have other STD disease conditions and infections, will be identified.~ 3. Pregnant women in the first and third trimester~Exclusion Criteria:~* are under 18 years of age~* unwillingness to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- I (Type: None): known syphilis infected patients
- U (Type: None): presumed uninfected patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Permission to Collect Blood Over Time for Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, \>= 18 years old. There are no ethnic restrictions.~* Active cancers of the GI tract (gastroesophageal, colorectal, or pancreatic-biliary) that have completed TNM staging by the American Joint Committee on Cancer; stage III disease if diagnosed within 2 months and all stage IV disease~* Ability to understand and the willingness to sign a written informed consent document.~* Existing staging CT imaging study~Exclusion Criteria:~* Life expectancy \< 6 months~* History of deep vein thrombosis (DVT) or pulmonary embolism (PE)~* Known pregnancy or positive urine pregnancy test in pre-menopausal women~* On anticoagulant therapy (heparin, warfarin, direct thrombin inhibitors)~* No CT imaging studies, or contraindications to undergoing CT imaging~* Existing or anticipated need for a tunneled central venous catheter~* Clinic visitation to Stanford Cancer center for secondary consultation purposes only~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be admitted to the ICU~* Have digital ischemia and~* Be on a vasopressor infusion~Exclusion Criteria:~* Patients with a history of systemic sclerosis~* Patients actively receiving aminoglycoside antibiotics - aminoglycosides may potentiate the effect of Botox~* Patients who have previously received botulinum toxin (A or B) injections~* Patients with a history of disorders of neuromuscular transmission (e.g myasthenia gravis, Lambert-Eaton, etc.) - Botox may have a lasting effect in these patients given their disorder~* Patients with clinical evidence of an infection in either forearm or hand~* Patients with a history of sensitivity to albumin - Botox is sold in powder form and there is albumin in the formulation~* Pregnancy - Botox is a class C medication~* Rheumatoid Arthritis~* Upper extremity arterio-venous graft or fistula~* Digital necrosis~* History of hand amputation~* Patients whom the intensive care attending physician deems will expire within 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botox injection (Type: EXPERIMENTAL): Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Implanted COGNIS device or future commercially available Boston Scientific CRT-D, that contains the Sensor Trend for Respiratory Rate, with a right ventricular lead and left ventricular lead actively implanted~* Respiratory Sensor programmed On~* Classified as having NYHA Class III heart failure documented, in the past 12 months~* Age 18 or above, or of legal age to give informed consent specific to state and national law~* Willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center and at the intervals defined by this protocol~Exclusion Criteria:~* Inability or refusal to sign the patient Informed Consent~* Inability or refusal to comply with the follow-up schedule~* Patients that have received routinely scheduled intravenous inotropic therapy as part of their drug regimen within the past 90 days~* Patients prescribed to positive airway pressure therapy~* A life expectancy of less than 180 days, per physician discretion~* Enrolled in any concurrent study without prior written approval from Boston Scientific CRM~* Women who are pregnant or plan to become pregnant in the next twelve months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: None): Heart failure patients with an implanted CRT-D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis ADHD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)~* At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale-IV-Parent Version~* Cannabis Abuse or dependence based on the DSM-IV-TR, and using a minimum of 5 joints per week~Exclusion Criteria:~* Weight under 20 kilograms (kg)~* Patients at serious suicidal risk~* Patients with alcohol or drug abuse (other than cannabis)~* Patients who in the investigator's judgement are likely to need psychotropic medication + psychotherapy apart from atomoxetine

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): 0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Antidepressant Effect of Right Temporal Low Frequency rTMS Compared to Sham

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients admitted to Århus university Hospital , Risskov or outpatients from the psychiatry district centres or practising specialist in the area.~* Moderate - severe depression according to ICD-10/ DSM-IVR~* Age 18-80 years~* Total Hamilton score ( 17-items) of ≥ 18 or subscale score ≥ 9~* Right handed~Exclusion Criteria:~* Organic brain disease~* Epilepsy in growing age~* Metallic objects as the result of a chest or Brain surgery~* Cardiac pacemakers~* Somatic diseases associated with brain dysfunction~* Pregnancy~* Suicide risk of severe degree~* Severe agitation or delirium~* Alcohol and drug dependency~* Ongoing Electroconvulsive treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- repetitive transcranial magnetic stimulation (Type: ACTIVE_COMPARATOR): Low frequency ( 1 HZ) rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
- Placebo stimulation (Type: SHAM_COMPARATOR): Sham- rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM V criteria for Bipolar I disorder (manic or mixed); age 10 - 17 years.~Exclusion Criteria:~* Imminent risk of suicide or homicide, as judged by the site investigator; any history of serious or unstable medical illness, including risk for QT prolongation.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- ziprasidone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Parastomal Hernia by Primary Mesh Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Permanent end-colostomy after surgery for rectosigmoid cancer with extirpation or Hartmann's procedure.~Exclusion Criteria:~* ASA \> 3~* Acute surgery~* Known immune deficiency~* Surgery with insertion of foreign body (orthopaedic prosthesis, mechanical or bio-logical heart valve etc.) within the last 3 months.~* Pregnancy~* Known inflammatory bowel disease~* Lack of written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- onlay mesh (Type: ACTIVE_COMPARATOR): None
- sublay mesh (Type: ACTIVE_COMPARATOR): None
- no mesh (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chylothorax Following Heart Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in the congenital surgery database~* patients have developed post-operative chylous effusions~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inflammation and Oxidative Stress of Adipose Tissue in Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male between 18 and 70 years old~* Apnea Hypopnea Index \> 30/h and \> 5% TST with SaO2 \< 90%~* patients obese (BMI \> 33kg/m2) or non obese (BMI \< 27kg/m2)~Exclusion Criteria:~* Female~* coronary ischemic disease, past history of CVA~* chronic pulmonary disease measured by arterial gasometry (PaO2 \< 60mmHg and/or PaCO2 \> 45mmHg)~* known hepatic disease~* alcohol consumption \> 3 units/day~* sleepiness considered to be dangerous by the investigator~* patient having an hazardous work regarding to awareness~* patient being under anticoagulant, antiplatelet drug or having an active stent or bleeding disorder~* patient having an inflammatory syndrome (C-reactive Protein \> 10)~* any allergy to local anaesthetics~* chronic muscle pain~* contraindication to MRI

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- obese + cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
- obese + Sham cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
- non-obese + cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
- non-obese + Sham cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* VATS~* ASA 1,2 or 3~* Minimum weight of 50 kg~* Patient able to consent~Exclusion Criteria:~* Patient refusal~* Patient unable to understand PCA~* Contraindication to rachianalgesia~* Zona~* Pregnancy~* Over 30 mg of morphine during the last 24 hours~* Use of Pregabalin, Gabapentin, Doluxetin, Amitriptyline or NSAI in a context of chronic pain~* Severe allergic reaction to morphine, hydromorphone, sufentanil or local anesthetic~* Intubation over 1 hour after surgery (unability to use PCA)~* High risk of conversion to thoracotomy~* Unable to perform rachianalgesia due to technical difficulties

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intrathecal Morphine/Sufentanil and PCA (Type: ACTIVE_COMPARATOR): Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
- PCA alone (Type: PLACEBO_COMPARATOR): Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient 18 years old and more~* with multiple sclerosis according to the criteria of Mac Donald 2010 : relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)~* for which treatment with dimethyl-fumarate has been prescribed~* followed at the Rothschild Foundation in the Neurology Department~* having given written consent to participation in the study~Exclusion Criteria:~* pregnant or breastfeeding woman~* patient with a measure of legal protection~* subject unaffiliated insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with recurring-remitting MS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients who have had a CR, PR or SD after 1st line therapy based on Irinotecan+Bevacizumab~* Paraffin block from the primary tumor in order to perform tha mutational analysis of the KRAS gene~* Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit),renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~Exclusion Criteria:~* Presence of central nervous system or brain metastases~* Pregnant or lactating woman~* Life expectancy \< 3 months~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow or in the field where the treatment target is located~* Peripheral neuropathy grade ≥2~* Known hypersensitivity to Erbitux~* Metastatic infiltration of the liver \>50%~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy~* Active infection~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer~* Psychiatric illness or social situation that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Irinotecan+Erbitux -\> XELOX+Erbitux
- 2 (Type: EXPERIMENTAL): XELOX+Erbitux -\>Irinotecan+Erbitux

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues